Palbociclib in Combination With Adjuvant Endocrine Therapy for Hormone Receptor Positive, HER2 Negative Invasive Breast Cancer

NCT02040857 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

162

Enrollment

OTHER

Sponsor class

Conditions

Breast Cancer

Interventions

DRUG: Palbociclib
DRUG: Aromatase Inhibitor

Sponsor

Dana-Farber Cancer Institute

Collaborators

[object Object]